ES2620379T3 - Quinolina y quinoxalina amidas como moduladores de canales de sodio - Google Patents
Quinolina y quinoxalina amidas como moduladores de canales de sodio Download PDFInfo
- Publication number
- ES2620379T3 ES2620379T3 ES14704054T ES14704054T ES2620379T3 ES 2620379 T3 ES2620379 T3 ES 2620379T3 ES 14704054 T ES14704054 T ES 14704054T ES 14704054 T ES14704054 T ES 14704054T ES 2620379 T3 ES2620379 T3 ES 2620379T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- halogen
- substituted
- units
- adjacent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 title 1
- -1 quinoxaline amides Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 19
- 229910052736 halogen Inorganic materials 0.000 abstract 17
- 150000002367 halogens Chemical class 0.000 abstract 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000002950 monocyclic group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 229910052717 sulfur Chemical group 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Un compuesto de fórmula I**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que, independientemente para cada caso: Y es CH o N; Ar1 es un anillo aromático monocíclico de 5-6 miembros que tiene 0-4 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre, en donde dicho anillo está opcionalmente fusionado a un anillo aromático monocíclico de 5 miembros que tiene 0-4 heteroátomos seleccionados independientemente de nitrógeno, oxígeno, o azufre, en el que Ar1 tiene sustituyentes m, seleccionados cada uno independientemente de-WRW; m es un número entero de 0 a 5 inclusive; W es un enlace o alquilo C1-C6 en el que dicho alquilo C1-C6 está sustituido con 0-6 halógeno, en donde hasta dos unidades de CH2 no adyacentes de dicho alquilo C1-C6 pueden sustituirse con -O-, -CO-, -S-, -SO-, o -SO2-; RW está ausente, H, halógeno, OH, NH2, NHR', NO2, CN, CF3, OCF3, o un anillo monocíclico de 3-6 miembros saturado, parcialmente insaturado, o totalmente insaturado que tiene 0-4 heteroátomos independientemente seleccionados de nitrógeno, oxígeno, o azufre; R' es alquilo C1-C6; R1 es H, halógeno, CN, o alquilo C1-C6 en el que dicho alquilo C1-C6 está sustituido con 0-6 halógeno y en donde hasta dos unidades no adyacentes CH2 de dicho alquilo C1-C6 pueden sustituirse con -O-; R2 es H, halógeno, CN, o alquilo C1-C6 en el que dicho alquilo C1-C6 está sustituido con 0-6 halógeno, en donde hasta dos unidades no adyacentes CH2 de dicho alquilo C1-C6 pueden sustituirse con -O-; R3 es H, halógeno, CN, o alquilo C1-C6 en el que dicho alquilo C1-C6 está sustituido con 0-6 halógeno, en donde hasta dos unidades no adyacentes CH2 de dicho alquilo C1-C6 pueden sustituirse con -O-; R4 es H, halógeno, CN, o alquilo C1-C6 en el que dicho alquilo C1-C6 está sustituido con 0-6 halógeno, en donde hasta dos unidades no adyacentes CH2 de dicho alquilo C1-C6 pueden sustituirse con -O-; R5 es H, halógeno, CN, o -XRX; R5' es H, halógeno, CN, o -XRX; R6 es H, halógeno, CN, o -XRX; R6' es H, halógeno, CN, o -XRX; R7 es H, halógeno, CN, o -XRX; X es un enlace o alquilo C1-C6 en el que dicho alquilo C1-C6 está sustituido con 0-6 halógeno, en donde hasta dos unidades de CH2 no adyacentes de dicho alquilo C1-C6 pueden sustituirse con -O-; y RX está ausente, H o C3-C8 cicloalifático, en donde hasta dos unidades no adyacentes CH2 de dicho C3-C8 cicloalifático puede reemplazarse por -O- y dicho C3-C8 cicloalifático está sustituido con 0-3 sustituyentes seleccionados de halógeno y alquilo C1-C4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759300P | 2013-01-31 | 2013-01-31 | |
PCT/US2014/013662 WO2014120815A1 (en) | 2013-01-31 | 2014-01-29 | Quinoline and quinazoline amides as modulators of sodium channels |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2620379T3 true ES2620379T3 (es) | 2017-06-28 |
Family
ID=50073532
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14704054T Active ES2620379T3 (es) | 2013-01-31 | 2014-01-29 | Quinolina y quinoxalina amidas como moduladores de canales de sodio |
Country Status (20)
Country | Link |
---|---|
US (2) | US9139529B2 (es) |
EP (1) | EP2951168B1 (es) |
JP (1) | JP6362623B2 (es) |
KR (1) | KR102226587B1 (es) |
CN (1) | CN105073738B (es) |
AR (1) | AR095192A1 (es) |
AU (1) | AU2014212426B8 (es) |
BR (1) | BR112015017997B1 (es) |
CA (1) | CA2898650C (es) |
ES (1) | ES2620379T3 (es) |
HK (1) | HK1217691A1 (es) |
HU (1) | HUE032169T2 (es) |
IL (1) | IL240091B (es) |
MX (1) | MX368833B (es) |
NZ (1) | NZ710111A (es) |
RU (1) | RU2683788C2 (es) |
SG (1) | SG11201505952WA (es) |
TW (1) | TWI631105B (es) |
WO (1) | WO2014120815A1 (es) |
ZA (1) | ZA201505326B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014212426B8 (en) * | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Quinoline and Quinoxaline Amides as Modulators of Sodium Channels |
SI2953931T1 (sl) | 2013-01-31 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Piridon amidi kot modulatorji natrijevih kanalov |
US11203571B2 (en) | 2013-07-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
RU2016135637A (ru) | 2014-02-06 | 2018-03-12 | Эббви Инк. | 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение |
EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
CN111065383A (zh) | 2017-07-11 | 2020-04-24 | 沃泰克斯药物股份有限公司 | 用作钠通道调节剂的羧酰胺 |
EP3752152A1 (en) | 2018-02-12 | 2020-12-23 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
WO2020014243A1 (en) | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
US20220227732A1 (en) * | 2018-07-09 | 2022-07-21 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
CN108997230B (zh) * | 2018-07-26 | 2020-08-04 | 山东大学 | 具有基质金属蛋白酶抑制活性的喹喔啉衍生物及其制备方法和应用 |
SG11202104326TA (en) | 2018-11-02 | 2021-05-28 | Merck Sharp & Dohme | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
AU2019404022A1 (en) | 2018-12-19 | 2021-07-08 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
JP7494181B2 (ja) | 2018-12-19 | 2024-06-03 | セルジーン コーポレイション | 置換3-((3-アミノフェニル)アミノ)ピペリジン-2,6-ジオン化合物、その組成物、及びそれを用いた治療方法 |
US20220110923A1 (en) | 2019-01-10 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
US20230062053A1 (en) | 2019-01-10 | 2023-03-02 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
BR112021026395A2 (pt) * | 2019-06-27 | 2022-02-08 | Glaxosmithkline Ip Dev Ltd | Compostos de 2,3-di-hidroquinazolina como inibidores de nav1.8 |
CN110698418B (zh) * | 2019-09-11 | 2022-07-01 | 广西师范大学 | 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用 |
TWI770607B (zh) * | 2019-09-12 | 2022-07-11 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物及其製備方法和用途 |
CR20220316A (es) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio |
CN114437062B (zh) * | 2020-04-30 | 2024-05-17 | 成都海博为药业有限公司 | 一种可作为钠通道调节剂的化合物及其用途 |
BR112022025805A2 (pt) | 2020-06-17 | 2023-01-10 | Merck Sharp & Dohme Llc | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir um distúrbio, condição ou doença |
CN112225695B (zh) * | 2020-12-15 | 2021-03-02 | 上海济煜医药科技有限公司 | 一种氮氧化合物及其制备方法和用途 |
JP2023554430A (ja) * | 2020-12-18 | 2023-12-27 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Nav1.8阻害剤としての含窒素2,3-ジヒドロキナゾリノン化合物 |
CR20230519A (es) | 2021-05-07 | 2024-01-19 | Merck Sharp & Dohme Llc | Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 |
WO2022256622A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
CN117794919A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂 |
WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
EP4347033A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
JP2024520649A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | (2r,3s,4s,5r)-4-[[3-(3,4-ジフルオロ-2-メトキシ-フェニル)-4,5-ジメチル-5-(トリフルオロメチル)テトラヒドロフラン-2-カルボニル]アミノ]ピリジン-2-カルボキサミドを含む固体剤形及び投与レジメン |
EP4347032A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
AR126669A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
AR126670A1 (es) | 2021-08-02 | 2023-11-01 | Eurofarma Laboratorios S A | COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS |
WO2023138599A1 (zh) * | 2022-01-18 | 2023-07-27 | 成都康弘药业集团股份有限公司 | 芳香并环类Nav1.8抑制剂及其用途 |
TW202408501A (zh) | 2022-04-22 | 2024-03-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
FR2377400A2 (fr) | 1977-01-18 | 1978-08-11 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
DE3210063A1 (de) | 1982-03-19 | 1983-09-22 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
FR2530633A1 (fr) | 1982-06-03 | 1984-01-27 | Roussel Uclaf | Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, et les compositions les renfermant |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
CN1018837B (zh) | 1991-03-12 | 1992-10-28 | 淄博齐新塑料厂 | 改性聚丙烯洗衣机内桶料及制备 |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
NZ337698A (en) * | 1997-04-04 | 2001-07-27 | Pfizer Prod Inc | Nicotinamide derivatives for selective inhibition of phosphodiesterase type 4 (PDE4) and the production of tumour necrosis factor (TNF) useful for the treatment of respiratory, rheumatoid and allergic diseases |
DE69831506T2 (de) * | 1997-12-22 | 2006-06-29 | Pharmacia & Upjohn Co. Llc, Kalamazoo | 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe |
JP2007501804A (ja) * | 2003-08-08 | 2007-02-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物 |
BRPI0513717A (pt) | 2004-07-23 | 2008-05-13 | Pfizer | derivados de piridina |
NZ596413A (en) | 2006-04-11 | 2013-03-28 | Vertex Pharma | Phenyl-sulfinyl-sulfamoylphenyl-benzamide derivatives that inhibit voltage-gated sodium channels |
KR101504773B1 (ko) * | 2007-03-23 | 2015-03-20 | 암젠 인크 | 헤테로시클릭 화합물 및 그의 용도 |
SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
AP2516A (en) | 2007-05-03 | 2012-11-26 | Pfizer Ltd | 2-Pyridine carboxamide derivatives as sodium channel modulators |
WO2009049183A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Aryl amides useful as inhibitors of voltage-gated sodium channels |
US8519137B2 (en) | 2007-10-11 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
JP5436434B2 (ja) * | 2007-10-11 | 2014-03-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位開口型ナトリウムチャネルの阻害剤として有用なアミド |
US20100113461A1 (en) * | 2008-10-29 | 2010-05-06 | Gilead Palo Alto, Inc. | Substituted heterocyclic compounds |
WO2010056865A1 (en) * | 2008-11-14 | 2010-05-20 | Gilead Palo Alto, Inc. | Quinoline derivatives as ion channel modulators |
TWI461197B (zh) * | 2009-03-12 | 2014-11-21 | 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier | |
WO2011140425A1 (en) | 2010-05-06 | 2011-11-10 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
ES2525581T3 (es) * | 2010-07-12 | 2014-12-26 | Pfizer Limited | Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje |
DK2670752T3 (en) | 2011-02-02 | 2016-07-04 | Vertex Pharma | PYRROLOPYRAZINE SPIROCYCLIC PIPERIDINAMIDE AS ION CHANNEL MODULATORS |
JP5940562B2 (ja) | 2011-02-18 | 2016-06-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド |
ES2618929T3 (es) | 2011-03-14 | 2017-06-22 | Vertex Pharmaceuticals Incorporated | Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico |
WO2014120820A1 (en) | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
SI2953931T1 (sl) | 2013-01-31 | 2017-08-31 | Vertex Pharmaceuticals Incorporated | Piridon amidi kot modulatorji natrijevih kanalov |
AU2014212426B8 (en) * | 2013-01-31 | 2018-05-10 | Vertex Pharmaceuticals Incorporated | Quinoline and Quinoxaline Amides as Modulators of Sodium Channels |
US11203571B2 (en) | 2013-07-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
LT3080134T (lt) | 2013-12-13 | 2018-11-12 | Vertex Pharmaceuticals Incorporated | Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai |
-
2014
- 2014-01-29 AU AU2014212426A patent/AU2014212426B8/en active Active
- 2014-01-29 WO PCT/US2014/013662 patent/WO2014120815A1/en active Application Filing
- 2014-01-29 JP JP2015556111A patent/JP6362623B2/ja active Active
- 2014-01-29 AR ARP140100283A patent/AR095192A1/es unknown
- 2014-01-29 CA CA2898650A patent/CA2898650C/en active Active
- 2014-01-29 HU HUE14704054A patent/HUE032169T2/en unknown
- 2014-01-29 US US14/167,685 patent/US9139529B2/en active Active
- 2014-01-29 EP EP14704054.7A patent/EP2951168B1/en active Active
- 2014-01-29 CN CN201480007842.8A patent/CN105073738B/zh active Active
- 2014-01-29 TW TW103103693A patent/TWI631105B/zh active
- 2014-01-29 ES ES14704054T patent/ES2620379T3/es active Active
- 2014-01-29 SG SG11201505952WA patent/SG11201505952WA/en unknown
- 2014-01-29 MX MX2015009592A patent/MX368833B/es active IP Right Grant
- 2014-01-29 RU RU2015136770A patent/RU2683788C2/ru active
- 2014-01-29 BR BR112015017997-5A patent/BR112015017997B1/pt active IP Right Grant
- 2014-01-29 NZ NZ710111A patent/NZ710111A/en unknown
- 2014-01-29 KR KR1020157023582A patent/KR102226587B1/ko active IP Right Grant
-
2015
- 2015-07-22 IL IL240091A patent/IL240091B/en active IP Right Grant
- 2015-07-23 ZA ZA2015/05326A patent/ZA201505326B/en unknown
- 2015-07-30 US US14/813,911 patent/US9783501B2/en active Active
-
2016
- 2016-05-13 HK HK16105501.3A patent/HK1217691A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2620379T3 (es) | Quinolina y quinoxalina amidas como moduladores de canales de sodio | |
ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
MX351581B (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
AR082201A1 (es) | Bencenosulfonamidas utiles como inhibidores del canal de sodio | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
AR107694A1 (es) | Heteroarilos inhibidores de pad4 | |
NZ706775A (en) | Methylene linked quinolinyl modulators of ror-gamma-t | |
PH12015500776A1 (en) | Phenyl linked quinolinyl modulators of ror-gamma-t | |
AR094277A1 (es) | Derivados de fumarato sustituidos con deuterio | |
EA201491362A1 (ru) | Анестезирующие соединения и способы их применения | |
EA030199B9 (ru) | Терапевтически активные соединения и способы их применения | |
AR092538A1 (es) | Inhibidores de girasa triciclica | |
CY1123533T1 (el) | Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b | |
CY1117688T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
MX343225B (es) | Nuevos derivados de aril-benzocicloalquil-amida. | |
MX2016007566A (es) | Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4. | |
EA201491276A1 (ru) | Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2 | |
EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
CY1119296T1 (el) | Ενωση δικαρβοξυλικου οξεος | |
EA201590669A1 (ru) | Производные n-(2-(циклический амин)этил)бензамида в качестве ингибиторов p2x7 | |
EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 | |
MX2013005753A (es) | Nuevos derivados de biaril amida. |